ACR Convergence 2023

November 10-15, 2023. San Diego, CA.

View by Number View by Title View Sessions

Sunday, November 12, 2023

4:00PM-5:30PM: Abstract Number: 0821

Effects of Sprifermin on a Novel Outcome of Osteoarthritis Symptom Progression: Post Hoc Analysis of the FORWARD Study

Abstracts: Osteoarthritis I: Clinical Trials

4:00PM-5:30PM: Abstract Number: 0839

Efficacy and Safety of Nipocalimab in Patients with Moderate to Severe Active Rheumatoid Arthritis (RA): The Multicenter, Randomized, Double-blinded, Placebo-controlled Phase 2a IRIS-RA Study

Abstracts: RA – Treatments I: Novel RA Treatments & Mechanisms of Action

4:00PM-5:30PM: Abstract Number: 0818

Efficacy of XT-150, a Novel Non-Viral Gene Therapy Delivering IL-10v, on Moderate to Severe Pain Due to Osteoarthritis of the Knee: Results of a Phase 2 Trial

Abstracts: Osteoarthritis I: Clinical Trials

4:00PM-5:30PM: Abstract Number: 0844

Facet Joint Inflammation Is Rare, but When Present It Is Associated with Facet Joint Ankylosis in Radiographic Axial Spondyloarthritis Patients from the SIAS Cohort

Abstracts: Spondyloarthritis Including Psoriatic Arthritis – Diagnosis, Manifestations, & Outcomes I: AxSpA

4:00PM-5:30PM: Abstract Number: 0822

From Biomarkers to Endotypes: Data-driven Identification of Knee Osteoarthritis Patients Subtypes

Abstracts: Osteoarthritis I: Clinical Trials

4:00PM-5:30PM: Abstract Number: 0840

Head-to-Head Comparison of TLL-018 and Tofacitinib in Patients with Active Rheumatoid Arthritis: Final Results from a Phase IIa Study

Abstracts: RA – Treatments I: Novel RA Treatments & Mechanisms of Action

4:00PM-5:30PM: Abstract Number: 0799

Human Chimeric Antigen Receptor (CAR)-Tregs Targeting OX40L for Treatment of Systemic Lupus Erythematosus

Abstracts: T Cell Biology & Targets in Autoimmune & Inflammatory Disease

4:00PM-5:30PM: Abstract Number: 0803

IL10 Inhibits Toll-like Receptor-9-induced T Cell Receptor-mediated T Cell Activation in Macrophage Activation Syndrome

Abstracts: T Cell Biology & Targets in Autoimmune & Inflammatory Disease

4:00PM-5:30PM: Abstract Number: 0807

Inferring Disease Activity Scores and Low Disease Activity at Registry Visits Based on Structured and Narrative Data from Electronic Health Records

Abstracts: Health Services Research I

4:00PM-5:30PM: Abstract Number: 0838

Infusion of Etanercept into the Peripheral Lymphatics Significantly Reduces Disease Activity in Rheumatoid Arthritis Patients with Inadequate Response to Subcutaneous Injections

Abstracts: RA – Treatments I: Novel RA Treatments & Mechanisms of Action

4:00PM-5:30PM: Abstract Number: 0797

Innate Lymphoid Cells Enhance Development of CD4+ T-cell Driven Autoimmune Arthritis

Abstracts: RA – Animal Models

4:00PM-5:30PM: Abstract Number: 0815

Intermittent Fasting Reduces Crystal-induced Inflammation

Abstracts: Metabolic & Crystal Arthropathies – Basic & Clinical Science

4:00PM-5:30PM: Abstract Number: 0828

Item Reduction and Validation of the Cutaneous Lupus Erythematosus Quality of Life Questionnaire

Abstracts: Patient Outcomes, Preferences, & Attitudes I: Assessment Tools

4:00PM-5:30PM: Abstract Number: 0812

Length of Synovial Fluid Monosodium Urate Crystals According to Sonographic Articular Deposits: Advancing in the Crystallization Process

Abstracts: Metabolic & Crystal Arthropathies – Basic & Clinical Science

4:00PM-5:30PM: Abstract Number: 0801

LncRNA PIGL-217 Regulates Th17 Differentiation by Targeting miR-5008-5p and Suppressing FoxO1 in Behçet’s Disease

Abstracts: T Cell Biology & Targets in Autoimmune & Inflammatory Disease

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.